Abstract
Get full access to this article
View all access options for this article.
References
1.
Marchione
M
. 2018 . Early results boost hopes for historic gene editing attempt . Associated Press , September 5 . Available at: www.apnews.com/2543a04b925c443b9ad3987f4209e68e/Early-results-boost-hopes-for-historic-gene-editing-attempt (accessed September 7 , 2018
2.Sangamo Therapeutics . 2018 . Sangamo announces 16 week clinical results including reductions in glycosaminoglycans in phase 1/2 trial evaluating SB-913, a zinc finger nuclease genome editing treatment for MPS II (Hunter Syndrome) . Available at: https://investor.sangamo.com/press-releases/detail/423/sangamo-announces-16-week-clinical-results-including (accessed September 7 , 2018
3.Astellas Pharma . 2018 . Astellas announces acquisition of Quethera . Available at: https://newsroom.astellas.us/2018-08-10-Astellas-Announces-Acquisition-of-Quethera (accessed September 7 , 2018
4.Quethera . 2018 . Neuroprotective therapy company Quethera reveals gene therapy results at ARVO . Available at: www.prweb.com/releases/quethera/arvo/prweb14339704.htm (accessed September 7 , 2018
5.Spark Therapeutics . 2018 . Spark Therapeutics reports second quarter 2018 financial results and recent business progress . Available at: http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-reports-second-quarter-2018-financial-results (accessed September 7 , 2018
6.Regeneron Pharmaceuticals and bluebird bio . 2018 . Regeneron and bluebird bio announce collaboration to discover, develop and commercialize new cell therapies for cancer . Available at: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bluebird-bio-announce-collaboration-discover?releaseid=1074041 (accessed September 7 , 2018
7.4D Molecular Therapeutics . 2018 . 4D Molecular Therapeutics raises $90 million Series B financing . Available at: www.4dmoleculartherapeutics.com/4d-molecular-therapeutics-raises-90-million-series-b-financing accessed September 7 , 2018
8.U.S. Securities and Exchange Commission . 2018 . Form 10-Q of Sarepta Therapeutics, filed August 8 . Available at: http://investorrelations.sarepta.com/static-files/0becd8e7-dbf2-4b1b-a7d9-7bb566ad7e12. accessed September 7 , 2018
9.Sarepta Therapeutics . 2018 . Sarepta Therapeutics signs long-term strategic investment and license agreements with Lacerta Therapeutics, gaining rights to multiple CNS-targeted gene therapy programs and access to important gene therapy talent and tools . Available at: http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-signs-long-term-strategic-investment-and (accessed September 7 , 2018